A Blended Intervention to Promote Physical Activity, Health and Work Productivity Among Office Employees

Physically Well But Worried Clinical Trial

Official title:

A Blended Intervention to Promote Physical Activity, Health and Work Productivity Among Office Employees Using Intervention Mapping: A Study Protocol for a Randomized Controlled Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04391270
• Other study ID #: 12609919
• Status: Completed
• Phase: N/A
• Start date: September 1, 2022
• Est. completion date: July 30, 2023

Study information

• Verified date: February 2024
• Source: Hong Kong Baptist University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary objective of this study is to examine between-group differences in changes of objectively measured MVPA levels (min/week) among a randomly selected sample of office employees who are physically inactive in Hong Kong.

Description:

Regular participation in moderate-to-vigorous physical activity (MVPA) is related to decreased risk of morbidity and mortality. Among working populations, lack of MVPA may also be a risk factor for absenteeism and presenteeism. Both traditional workplace-based and web-based interventions have been suggested as being effective in promoting participation MVPA, health-related outcomes, and work-related productivity. However, several challenges limit their application in real world contexts. A 'blended' intervention approach combining the two intervention strategies is proposed to overcome these limitations. The proposed intervention aims to utilize the blended approach to increase participation in MVPA, health-related outcomes, and work productivity among inactive workers.

Methods: The study will comprise of a three group cluster randomized controlled trial (cluster-RCT), comprising a three-month actual intervention and a nine-month behavioral follow-up period. The three groups will be: a web-based intervention group, a blended intervention group combining the web-based components with face-to-face workshops, and a control group. Physically inactive office employees (N = 141) from will be recruited and randomly assigned to the three groups by cluster randomization. The intervention mapping (IM) framework will be used for selecting and applying effective health behavioural theories and behavioural change techniques (BCTs) to the development, implementation and assessment of the intervention, which will be personally tailored. The primary outcome variable will be objectively measured MVPA using an accelerometer. Secondary outcomes will consist of indices of health including adiposity, blood pressure, blood sugar, blood lipids, self-reported depression, anxiety, stress, and health-related quality of life, and work-related variables including absenteeism and presenteeism.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 141
• Est. completion date: July 30, 2023
• Est. primary completion date: July 30, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• physically inactive (do NOT meet the WHO's recommended MVPA levels)

• office employees in Hong Kong.

Exclusion Criteria:

• participants are engaging other ongoing programs involving MVPA promotion

• if they report any conditions preventing them from being active.

Related Conditions & MeSH terms

• Physically Well But Worried

Intervention

Behavioral:
• blended intervention
A blended intervention group combining the web-based components with face-to-face workshops and posters
• web-based intervention
A web-based intervention only referred to the use of internet without traditional face-to-face workshops and posters

Locations

Country	Name	City	State
Hong Kong	Department of Sport, Physical Education, and Health	Kowloon Tong

Sponsors (1)

Lead Sponsor	Collaborator
Hong Kong Baptist University

Country where clinical trial is conducted

Hong Kong, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	moderate-to-vigorous physical activity (MVPA) levels	examine between-group differences in changes of objectively measured MVPA levels (min/week) among a randomly selected sample of office employees who are physically inactive in Hong Kong	baseline, 13 weeks, 25 weeks
Secondary	changes of self-report MVPA levels (min/week)	To examine between-group differences in changes of self-reported MVPA levels (min/week) in different domains among the sample.	baseline, 13 weeks, 25 weeks
Secondary	Height in meters	Height will be measured to the nearest 0.1 cm using a stadiometer.	baseline, 13 weeks, 25 weeks
Secondary	Weight in kilograms	Weight will be measured to the nearest 0.1 kg on a calibrated digital balance scale (Seca, max. 200 kg, Germany) with the participants wearing lightweight clothing and no shoes.	baseline, 13 weeks, 25 weeks
Secondary	Body mass index (BMI, kg/m2)	Body mass index (BMI, kg/m2) will be calculated from weight and height.	baseline, 13 weeks, 25 weeks
Secondary	Waist circumference (cm)	Waist circumference (cm) will be measured midway between the lowest rib margin and the top of the iliac crest at the end of gentle expiration	baseline, 13 weeks, 25 weeks
Secondary	%Body fat	%BF will be assessed by a Tanita TBF-410 Body Composition Analyzer (Tanita Corporation, Tokyo, Japan) using foot-to-foot bioelectrical impedance analysis (BIA).	baseline, 13 weeks, 25 weeks
Secondary	Blood pressure (mmHg)	Blood pressure will be measured using the Omron M6 Compact (HEM-7000-E, Omron Healthcare Corporation, Kyoto, Japan) following standard measurement protocols.	baseline, 13 weeks, 25 weeks
Secondary	Hemoglobin A1C (%)	Hemoglobin A1C will be measured using the Reflotron ® Plus system (Roche Diagnostics, F. Hoffmann-La Roche Ltd., Burgess Hill, UK).	baseline, 13 weeks, 25 weeks
Secondary	Depression, anxiety and stress	Depression, anxiety and stress will be measured using the Chinese version of the Depression Anxiety Stress Scale (DASS-21)	baseline, 13 weeks, 25 weeks
Secondary	Presenteeism	It will be assessed using presenteeism questions derived from the WHO's Heath and Work Performance Questionnaire (HPO).	baseline, 13 weeks, 25 weeks
Secondary	High-density lipoprotein (mmol/L)	high-density lipoprotein will be measured using the Reflotron ® Plus system (Roche Diagnostics, F. Hoffmann-La Roche Ltd., Burgess Hill, UK).	baseline, 13 weeks, 25 weeks
Secondary	Triglyceride (mmol/L)	Triglyceride will be measured using the Reflotron ® Plus system (Roche Diagnostics, F. Hoffmann-La Roche Ltd., Burgess Hill, UK).	baseline, 13 weeks, 25 weeks